Save to Existing Project
Save to a New Project
Recently gaining patent approval, this product is for Uveitis and Irritable Bowel Syndrome....
MECHANISM OF ACTION
Low down the inflammatory cascade.
Considerable in-vitro data has been generated showing this product to have excellent potential as an anti-inflammatory agent. The company have selected Uveitis as a target indication and have Irritable Bowel Syndrome as a follow-up.
Looking for partners to move into the clinic.
Type of Business Relationship Sought
Funding, joint-venture, out-licensing
Last Updated Aug 2016